Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis DOI Creative Commons
Anita Florit, Elizabeth J. de Koster,

Serena Sassano

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Abstract Purpose This study aims to systematically review and perform a meta-analysis compare the diagnostic performance of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ F]FDG) in gynaecological cancers. Methods A comprehensive search PubMed/MEDLINE EMBASE was conducted updated October 25, 2024, identify clinical studies evaluating FAPI [ F]FDG PET/CT or PET/MR patients with cancer. Quality assessed using QUADAS-2 tool (Quality Assessment Diagnostic Accuracy Studies). Per-lesion pooled estimates sensitivity, specificity, positive predictive value, negative value were calculated 95% confidence intervals. Results Ten included for qualitative assessment five focusing on ovarian cancer meta-analysis. The detection rates primary cervical ranged from 96 100% both radiopharmaceuticals. For tumour cancer, sensitivities 68 Ga-FAPI 92%, specificities 81% Nodal metastases higher compared Similarly, estimated 97% 88%, 83% 41%, respectively. At peritoneal analysis 70%, 93% visual scores, such as index, detected greater burden F]FDG. comparative PET semiquantitative parameters also performed. Conclusion Despite limited literature data, based FAPIs are promising alternative imaging cancers, particular nodal well detecting Larger prospective needed confirm these results promote inclusion practice. Clinical trial number Not applicable.

Language: Английский

Comparing the diagnostic performance of DSC-MRI and FAPI PET in differentiating tumor progression from treatment-related changes in IDH-Wildtype Glioblastoma: A pilot study DOI
Hasan Önner, Halil Özer, Burak Gezer

et al.

European Journal of Radiology, Journal Year: 2025, Volume and Issue: unknown, P. 112075 - 112075

Published: March 1, 2025

Language: Английский

Citations

0
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis DOI Creative Commons
Anita Florit, Elizabeth J. de Koster,

Serena Sassano

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Abstract Purpose This study aims to systematically review and perform a meta-analysis compare the diagnostic performance of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ F]FDG) in gynaecological cancers. Methods A comprehensive search PubMed/MEDLINE EMBASE was conducted updated October 25, 2024, identify clinical studies evaluating FAPI [ F]FDG PET/CT or PET/MR patients with cancer. Quality assessed using QUADAS-2 tool (Quality Assessment Diagnostic Accuracy Studies). Per-lesion pooled estimates sensitivity, specificity, positive predictive value, negative value were calculated 95% confidence intervals. Results Ten included for qualitative assessment five focusing on ovarian cancer meta-analysis. The detection rates primary cervical ranged from 96 100% both radiopharmaceuticals. For tumour cancer, sensitivities 68 Ga-FAPI 92%, specificities 81% Nodal metastases higher compared Similarly, estimated 97% 88%, 83% 41%, respectively. At peritoneal analysis 70%, 93% visual scores, such as index, detected greater burden F]FDG. comparative PET semiquantitative parameters also performed. Conclusion Despite limited literature data, based FAPIs are promising alternative imaging cancers, particular nodal well detecting Larger prospective needed confirm these results promote inclusion practice. Clinical trial number Not applicable.

Language: Английский

Citations

0